| 1 |
33468383 | Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen. | 2021 May |
3 |
| 2 |
33931939 | The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. | 2021 Aug |
1 |
| 3 |
32118594 | Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study. | 2020 Nov/Dec |
1 |
| 4 |
32331534 | The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1. | 2020 Sep 1 |
2 |
| 5 |
33014113 | Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p. | 2020 |
2 |
| 6 |
33035787 | Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. | 2020 Dec |
1 |
| 7 |
32184881 | Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers. | 2019 Fall |
2 |
| 8 |
29145602 | Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. | 2018 Feb 1 |
1 |
| 9 |
30048976 | Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. | 2018 |
2 |
| 10 |
28088319 | ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. | 2017 Feb |
3 |
| 11 |
28259288 | Biological and predictive role of ERCC1 polymorphisms in cancer. | 2017 Mar |
1 |
| 12 |
29153096 | Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. | 2017 Dec |
1 |
| 13 |
27366083 | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer. | 2016 |
1 |
| 14 |
25553091 | ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. | 2015 |
2 |
| 15 |
25690281 | XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. | 2015 May |
2 |
| 16 |
25723812 | The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver. | 2015 Apr |
4 |
| 17 |
25834456 | Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. | 2015 |
5 |
| 18 |
26161372 | ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. | 2015 Jun |
1 |
| 19 |
26372896 | Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. | 2015 Oct 20 |
2 |
| 20 |
26662383 | Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. | 2015 Dec 7 |
3 |
| 21 |
26770441 | Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. | 2015 |
1 |
| 22 |
23982883 | XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. | 2014 Mar 15 |
5 |
| 23 |
24220697 | Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. | 2014 Jan |
3 |
| 24 |
24300914 | Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. | 2014 Mar |
2 |
| 25 |
24318989 | Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. | 2014 Apr |
1 |
| 26 |
24520224 | Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil. | 2014 Jan |
4 |
| 27 |
24847383 | ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. | 2014 |
1 |
| 28 |
25175730 | Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy. | 2014 Aug 29 |
2 |
| 29 |
25339033 | The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. | 2014 |
4 |
| 30 |
23332421 | Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. | 2013 Jun |
1 |
| 31 |
23426424 | The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. | 2013 Mar |
5 |
| 32 |
23481186 | ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. | 2013 Apr 2 |
3 |
| 33 |
23543295 | Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. | 2013 Jun |
1 |
| 34 |
23604281 | Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy. | 2013 Jun |
3 |
| 35 |
24548447 | [Clinical values of detecting excision repair cross complementing 1 and top-isomerase I in individualized therapies of metastatic colorectal cancer]. | 2013 Dec 24 |
1 |
| 36 |
21940361 | Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. | 2012 Jan-Feb |
2 |
| 37 |
22181013 | Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. | 2012 Mar |
1 |
| 38 |
22994779 | GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. | 2012 |
2 |
| 39 |
23169295 | Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. | 2012 Dec 4 |
5 |
| 40 |
23209813 | KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. | 2012 |
4 |
| 41 |
24833529 | ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis. | 2012 Jan |
4 |
| 42 |
21278243 | ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. | 2011 Mar 15 |
4 |
| 43 |
21298384 | Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. | 2011 Oct |
1 |
| 44 |
21418871 | [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy]. | 2011 Jan 25 |
1 |
| 45 |
21787270 | Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. | 2011 Dec |
2 |
| 46 |
21855036 | A review of excision repair cross-complementation group 1 in colorectal cancer. | 2011 Sep |
1 |
| 47 |
21999595 | mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. | 2011 Nov |
1 |
| 48 |
22110208 | Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. | 2011 Nov |
5 |
| 49 |
22202337 | [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. | 2011 Nov |
1 |
| 50 |
19850635 | EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. | 2010 Mar |
2 |